Rasburicase for the treatment of tumor lysis in hematological malignancies
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rasburicase for the treatment of tumor lysis in hematological malignancies
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume 5, Issue 1, Pages 27-38
Publisher
Informa UK Limited
Online
2012-01-26
DOI
10.1586/ehm.11.73
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The clinical management of tumour lysis syndrome in haematological malignancies
- (2011) Andrew Will et al. BRITISH JOURNAL OF HAEMATOLOGY
- Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus
- (2010) Mitchell S. Cairo et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cloning, Purification, and Partial Characterization ofBacillus subtilisUrate Oxidase Expressed inEscherichia coli
- (2010) Pollyana Pfrimer et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone—Results of a Multicenter Phase III Study
- (2010) Jorge Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function
- (2009) Mariano Malaguarnera et al. EXPERT OPINION ON PHARMACOTHERAPY
- A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome
- (2009) Akira Kikuchi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome
- (2009) M. Shimada et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome
- (2008) Kyung A. Choi et al. ANNALS OF HEMATOLOGY
- Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study
- (2008) Kenichi Ishizawa et al. CANCER SCIENCE
- Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase
- (2008) Margit Hummel et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model
- (2008) P. Montesinos et al. HAEMATOLOGICA
- Consensus conference on the management of tumor lysis syndrome
- (2008) P. Tosi et al. HAEMATOLOGICA
- Fatal Acute Tumor Lysis Syndrome following Intrathecal Chemotherapy for Acute Lymphoblastic Leukemia with Meningeal Involvement
- (2008) Takaaki Konuma et al. INTERNAL MEDICINE
- Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
- (2008) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
- Transient Spontaneous Remission After Tumor Lysis Syndrome Triggered by a Severe Pulmonary Infection in an Adolescent Boy With Acute Lymphoblastic Leukemia
- (2008) Rong-Long Chen et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Elevated Uric Acid Increases the Risk for Kidney Disease
- (2008) R. P. Obermayr et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Production of a thermostable uricase by a novel Bacillus thermocatenulatus strain
- (2007) W LOTFY BIORESOURCE TECHNOLOGY
- Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia
- (2007) Scott C. Borinstein et al. PEDIATRIC BLOOD & CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started